Cytyc Announces First ThinPrep Imaging System Placement In Asia.

MARLBOROUGH, Mass. -- Cytyc Corporation (Nasdaq: CYTC), a leading women's health company, today announced the placement of the first ThinPrep(R) Imaging System in Asia at the University of Hong Kong (HKU) Cervical Cytology Screening Laboratory. The HKU Cervical Cytology Screening Laboratory currently processes approximately 80,000 ThinPrep(R) Pap Tests annually.

"Implementation of the ThinPrep Imaging System will save a lot of manpower and can reduce the error due to human fatigue," said Annie Cheung Nga-yin, M.D. pathologist in charge of the laboratory. "It improves the efficiency and ensures accuracy of cervical cytology screening."

In 2004, the Government of the Hong Kong Special Administrative Region (HKSAR) launched a territory wide cervical cancer screening program that estimated about 670,000 cervical cytology samples need to be screened and diagnosed each year. The introduction of new technology, together with well trained cytopathologists and cytotechnicians, are necessary to ensure the efficiency and effectiveness of cervical cytology screening.

Professor Cheung added, "The semi-automated technology for screening cervical samples will allow HKU laboratory to analyze 120,000 Pap tests a year, about 50 percent more than the current capacity." The HKU laboratory converted to the ThinPrep Pap Test in March 2000 and in 2001 became the first laboratory in Hong Kong accredited by the College of American Pathologists.

"We are very excited about our first placement of the ThinPrep Imaging System in Asia," said Patrick J. Sullivan, Cytyc's chairman, president, and chief executive officer. "We have been working with the University of Hong Kong for a number of years and believe this excellent institution is the ideal platform from which to launch the ThinPrep Imager into the Asian market."

The Cervical Cytology Screening Laboratory, Department of Pathology, Faculty of Medicine, the University of Hong Kong is responsible for reporting results of the analysis of cervical cytology samples from The Family Planning Association, a major contributor to the establishment of cervical cancer screening programs in Hong Kong. Nearly 1.2 million samples have been reported since 1991, with an average of 80,000 cases per year. Since 2004, the Laboratory has started to report cervical cytology samples from the Department of Obstetrics and Gynaecology, Faculty of Medicine, HKU and the Lady Helen Woo Women's Diagnostic & Treatment Center, located at Tsan Yuk Hospital.

Cytyc Corporation is a leading women's health company that designs, develops, manufactures, and markets innovative and clinically effective products. Cytyc products cover a range of women's health applications, including cervical cancer screening, breast cancer risk assessment, treatment of excessive menstrual bleeding, and treatment of breast cancer.

Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC. Cytyc and ThinPrep are registered trademarks of Cytyc Corporation.

Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to Cytyc's future financial condition, operating results and economic performance, and management's expectations regarding future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel, customers and proprietary technology, uncertainty of product development efforts and product acceptance, management of growth and product diversification, entry into new market segments, risks associated with litigation, the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and healthcare reimbursement policies, introduction of technologies that are disruptive to Cytyc's business and operations, the impact of new accounting requirements and governmental rules and regulations, as well as other risks detailed in Cytyc's filings with the Securities and Exchange Commission, including under the heading "Certain Factors Which May Affect Future Results" in its 2004 Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q filed with the Commission. Cytyc cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Cytyc disclaims any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.